PM1015

PM1015 is a monoclonal antibody that specifically targets CD73 (ecto-5'-nucleotidase), functioning as a CD73 inhibitor. By inhibiting CD73, which plays a role in the production of immunosuppressive adenosine in the tumor microenvironment, PM1015 aims to enhance anti-tumor immune responses. The drug is being developed primarily for the treatment of advanced solid tumors and liver cancer. It is currently undergoing phase 1 clinical trials to evaluate its safety, pharmacokinetics, and preliminary efficacy in patients with advanced malignant solid neoplasms[1][2][3][5]. The developer and active organization for this drug is Biotheus.

Other names

anti-CD73 monoclonal antibodyanti-CD-73 monoclonal antibodyanti-CD 73 monoclonal antibodyCD73 AntigenCD-73 AntigenCD 73 Antigen